Scarica l'app Stockscreener
32.43
7.69%
-2.70
Dopo l'orario di chiusura:
34.05
1.62
+5.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.13
Aprire:
$34.32
Volume 24 ore:
879.48K
Relative Volume:
1.12
Capitalizzazione di mercato:
$3.18B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-5.0124
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
-14.25%
1M Prestazione:
-21.09%
6M Prestazione:
-39.71%
1 anno Prestazione:
-31.12%
Intervallo 1D:
$32.07
$34.79
Intervallo di 1 settimana:
$32.07
$36.98
Portata 52W:
$32.07
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
32.43 | 3.18B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx stock hits 52-week low at $33.37 amid market challenges - Investing.com India
How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga
Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks
Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia
Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa
Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com
Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan
Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St
Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada
Ultragenyx pharmaceutical CFO sells $72,114 in common stock - Investing.com India
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline - TipRanks
FDA grants priority review to gene therapy for Sanfilippo type A - Sanfilippo News
Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of $165 Mi - GuruFocus.com
Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock By Investing.com - Investing.com Australia
Ultragenyx’s chief accounting officer sells $40,710 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical executive sells $607,881 in stock - Investing.com Australia
Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock - Investing.com India
Ultragenyx EVP Eric Crombez sells $376,584 in stock - Investing.com India
Ultragenyx EVP Eric Crombez sells $376,584 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical EVP sells $635,836 in stock - Investing.com India
Ultragenyx pharmaceutical EVP sells $635,836 in stock By Investing.com - Investing.com Canada
Ultragenyx CEO Emil Kakkis sells $4.15 million in stock By Investing.com - Investing.com UK
Ultragenyx’s chief accounting officer sells $40,710 in stock - Investing.com
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Ultragenyx EVP Karah Parschauer sells $128,223 in stock By Investing.com - Investing.com Canada
Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells - Law360
Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India
(RARE) Technical Pivots with Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ultragenyx Pharmaceutical Inc Azioni (RARE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kassberg Thomas Richard | CBO & EVP |
Mar 03 '25 |
Sale |
42.10 |
6,028 |
253,779 |
265,238 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Mar 03 '25 |
Sale |
42.10 |
12,846 |
540,817 |
75,287 |
| Crombez Eric | EVP and Chief Medical Officer |
Mar 03 '25 |
Sale |
42.10 |
8,945 |
376,584 |
71,922 |
| Pinion John Richard | See Remarks |
Mar 03 '25 |
Sale |
42.10 |
14,439 |
607,882 |
107,766 |
| KAKKIS EMIL D | President & CEO |
Mar 03 '25 |
Sale |
42.10 |
73,434 |
3,091,571 |
641,731 |
| KAKKIS EMIL D | President & CEO |
Feb 28 '25 |
Sale |
42.48 |
25,000 |
1,062,000 |
2,158,985 |
| Harris Erik | EVP & Chief Commercial Officer |
Mar 03 '25 |
Sale |
42.10 |
15,103 |
635,836 |
87,855 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Mar 03 '25 |
Sale |
42.10 |
967 |
40,711 |
50,265 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Feb 27 '25 |
Sale |
42.88 |
2,990 |
128,224 |
54,991 |
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):